ATC Group: R06AX29 Bilastine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R06AX29 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R06 Antihistamines for systemic use
3 R06A Antihistamines for systemic use
4 R06AX Other antihistamines for systemic use
5 R06AX29 Bilastine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 20 mg

Active ingredients in R06AX29

Active Ingredient Description
Bilastine

Bilastine is a non-sedating, long-acting histamine antagonist with selective peripheral Η1 receptor antagonist affinity and no affinity for muscarinic receptors.

Related product monographs

Title Information Source Document Type  
ILAXTEN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

New Zealand (NZ)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.